Zenas Biopharma Inc. (ZBIO US)
ZBIO US$28.82
20 minute delayed
14 days free access
Join Market Matters and get full access to all our Opinion + Action
Performance
Advanced charting functionality with the ability to amend timeframes, chart type & indicator selection, powered by TradingView.
Share price activity
Displays share price activity. Volume = number of shares traded, Turnover = value of shares traded, VWAP = volume-weighted average price for the day, sourced from Morningstar.
- Last (Price)
- 28.82
- Change
- ▲ 1.52 (5.57)
- Bid / Ask
- 21.50 - 32.56
- Volume
- 89,404
- Turnover
- 1,679,425
- Open
- 27.10
- Day Range
- 27.10 - 28.93
- VWAP
- 28.56
- Prev Close
- 27.30
- Last Trade
- 28/10 4:00pm
Key information
Displays key information on the security, sourced from Morningstar.
- Sector
- Healthcare
- Shares Issued
- 65,176,723
- NTA/Share
- 4.44
- Last Dividend
- —
- Dividend Ex Date
- —
- Dividend Pay Date
- —
Current (USD) · FY2025
Displays key financial data for the most recent fiscal year, in millions. Note - Per share data is in local currency terms irrespective of reporting currency, and may be different to the stated currency, sourced from Morningstar.
- Revenue
- 10.00
- EBITDA
- -382.58
- Profit
- -377.74
- Earnings Per Share (EPS)
- -8.44
- Dividend Per Share (DPS)
- —
- Yield %
- 0.00
- Market Cap
- 1,878.39
- Price to Earnings Ratio (P/E)
- -2.99
Estimates (USD) · FY2027
Displays consensus analyst’s estimates for key measures for the next fiscal year, sourced from Morningstar.
- Revenue
- 36.75
- EBITDA
- —
- Profit
- -337.38
- Earnings Per Share (EPS)
- -5.11
- Dividend Per Share (DPS)
- —
Quantitative rating
Displays Morningstar’s Quantitative Equity Research Rating for the security: a star rating from 1 (overvalued) to 5 (undervalued) from the share price against a fair value estimated by a statistical model of Morningstar’s analyst ratings, with the model’s economic moat, financial health and fair value uncertainty, sourced from Morningstar.
Undervalued
- Economic Moat
- None
- Financial Health
- Moderate
- Uncertainty
- Very High
Morningstar Quantitative Rating as of 22 OCT 2026.
Quantitative Equity Rating Methodology – view here
Fair value estimate
Displays Morningstar’s quantitative fair value estimate for the security against the current share price, with the band around it: the five-star price below which the model would rate the stock five stars and the one-star price above which it would rate it one star, sourced from Morningstar.
Five-star price 16.73 Fair value 38.28 One-star price 87.57
Morningstar Quantitative Rating as of 22 OCT 2026.
Quantitative valuation
Displays where the share price sits in Morningstar’s quantitative fair value band, from the five-star price (undervalued) to the one-star price (overvalued), with the fair value estimate, the price to fair value ratio, the model’s valuation label and its uncertainty rating, sourced from Morningstar.
Buy
Sell
- Fair Value
- 38.28
- Price / Fair Value
- 0.74
- Valuation
- Undervalued
- Uncertainty
- Very High
Morningstar Quantitative Rating as of 22 OCT 2026. The slider runs from the five-star price (16.73) to the one-star price (87.57).
Displays useful ratios for the security, NB the pricing date used, sourced from Morningstar.
| Ratios |
|---|
| Currency (Price/reporting): USD/USD |
| Exchange Rate: 1.0000 |
Price, volume and trading statistics for the security, sourced from Morningstar.
| Price - closing or last bid | 28.23 |
| Price - 12 month high | 44.43 |
| Price - 12 month low | 13.50 |
| Pricing date | 21 OCT 2026 |
| Volume - avg. trading volume for the last ten days | 0.54 |
| Market capitalization | 1,839.94 |
| 12 Month High price date | 24 DEC 2025 |
| 12 Month Low price date | 5 JAN 2026 |
| Volume - avg. trading volume for the last 3 months | 0.70 |
| Price - 1 Day % Change | 0.53% |
| Price - 13 week price percent change | -10.35% |
| Price - 26 week price percent change | 40.66% |
| Price - 5 Day % Change | 11.14% |
| Price - 52 week price percent change | 15.84% |
| Price - YTD price percent change | -22.83% |
| Price % Change Month To Date | -14.58% |
Earnings, dividends, cash flow and book value per share, sourced from Morningstar.
| EPS excluding extraordinary items - most recent fiscal year | -8.440 |
| EPS excluding extraordinary items - trailing 12 month | -9.630 |
| EPS Normalized - most recent fiscal year | -4.012 |
| Revenue/share - most recent fiscal year | 0.224 |
| Revenue/share - trailing 12 month | 0.019 |
| Book value per share - most recent fiscal year | 4.444 |
| Book value per share - most recent quarter | 3.902 |
| Book value (tangible) per share - most recent fiscal year | 4.444 |
| Book value (tangible) per share - most recent quarter | 3.902 |
| Cash per share - most recent fiscal year | 2.031 |
| Cash per share - most recent quarter | 3.104 |
| Cash Flow per share - most recent fiscal year | -3.874 |
| Cash Flow per share - trailing 12 month | -4.265 |
| Dividend per share - most recent fiscal year | — |
| Dividends per share - trailing 12 month | 0.000 |
| EBITD per share - trailing 12 month | -9.048 |
| EPS Basic excluding extraordinary items - most recent fiscal year | -8.440 |
| EPS Basic excluding extraordinary items - trailing 12 month | -9.630 |
| EPS including extraordinary items - most recent fiscal year | -8.440 |
| EPS including extraordinary items - trailing 12 month | -9.000 |
| Free Cash Flow per share - trailing 12 month | -4.265 |
Valuation multiples such as P/E, price to sales, price to book and enterprise value ratios, sourced from Morningstar.
| P/E excluding extraordinary items, most recent fiscal year | — |
| P/E Normalized, most recent fiscal year | — |
| Price to sales - most recent fiscal year | 1,510.60 |
| Price to Tangible Book - most fiscal year | 7.24 |
| Price to Free Cash Flow per Share - most recent fiscal year | — |
| Price to Cash Flow per share - trailing 12 month | — |
| Price to Book - most recent fiscal year | 7.24 |
| P/E excluding extraordinary items high, trailing 12 months | 3.57 |
| P/E excluding extraordinary items low, trailing 12 months | 1.11 |
| Net Debt, LFI | -345.27 |
| Net Debt, LFY | -341.87 |
| Dividend Yield - 5 Year Average | — |
| Dividend Yield - indicated annual dividend divided by closing price | — |
| Current Dividend Yield - Common Stock Primary Issue, LTM | 0.00% |
Cash flow, liquidity and leverage measures, sourced from Morningstar.
| Free Cash Flow - most recent fiscal year | -208.30 |
| LT debt/equity - most recent fiscal year | 0.09% |
| Payout ratio - most recent fiscal year | — |
| Total debt/total equity - most recent fiscal year | 0.55% |
| LT debt/equity - most recent quarter | 120.21% |
| Total debt/total equity - most recent quarter | 120.54% |
| Free Cash Flow - trailing 12 month | -228.21 |
| Payout ratio - trailing 12 month | — |
Key income statement lines for the most recent fiscal year, in millions, sourced from Morningstar.
| Revenue - most recent fiscal year | 10.00 |
| Revenue - trailing 12 month | 1.00 |
| EBITD - most recent fiscal year | -382.58 |
| EBITD - trailing 12 month | -484.13 |
| Earnings before taxes - most recent fiscal year | -377.82 |
| Earnings before taxes - trailing 12 month | -484.16 |
| Net Income available to common - most recent fiscal year | -377.74 |
| Net Income available to common - trailing 12 months | -484.38 |
| Earnings before taxes Normalized - most recent fiscal year | -179.69 |
| Net Income Available to Common, Normalized - most recent fiscal year | — |
| Earnings per Share, Normalized, Excluding Extraordinary Items, Avg. Diluted Shares Outstanding, TTM | -6.17 |
Profitability margins for the most recent fiscal year, sourced from Morningstar.
| Net Profit Margin % - 1st historical fiscal year | -3,777.37% |
| Net Profit Margin % - trailing 12 month | -48,438.40% |
| Operating margin - 1st historical fiscal year | -2,113.85% |
| Operating margin - trailing 12 month | -27,390.10% |
| Pretax margin - trailing 12 month | -48,416.40% |
| Pretax margin - 1st historical fiscal year | -3,778.16% |
| Operating Margin - 5 year average | — |
| Pretax Margin - 5 year average | — |
| Free Operating Cash Flow/Revenue, 5 Year Average | -6,963.36% |
| Free Operating Cash Flow/Revenue, TTM | -22,820.70% |
| Net Profit Margin - 5 year average | — |
Returns on average assets and equity for the fiscal year, the trailing 12 months and as 5 year averages, and net income and revenue per employee in whole currency, sourced from Morningstar.
| Return on average assets - most recent fiscal year | -110.94% |
| Return on average assets - trailing 12 month | -98.93% |
| Return on average equity - most recent fiscal year | -148.14% |
| Return on average equity - trailing 12 month | -192.04% |
| Return on average assets - 5 year average | -98.19% |
| Return on average equity - 5 year average | — |
| Net Income/employee - most recent fiscal year | — |
| Revenue/employee - most recent fiscal year | — |
Growth in revenue, earnings, dividends and book value over recent periods, sourced from Morningstar.
| Revenue growth rate, 5 year | — |
| EPS growth rate, 5 year | — |
| Growth rate% - dividend, 3 year | — |
| Revenue/share (5 yr growth) | — |
| Growth rate% - Revenue, 3 year | — |
| Growth rate% - EPS, 3 year | — |
| Book value per share growth rate, 5 year | — |
| Capital Spending growth rate, 5 year | — |
| Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR | — |
Displays analyst’s forecasts for key measures. The estimates can be expanded to see the spread of the calls. Full lines = reported, and dotted lines are forward estimates. Click a measure to add or remove it from the chart, sourced from Morningstar.
Financial forecast (USD, millions except per share)
| Actuals | Estimates | |||||||
| 2025 | 2026 | 2027 | 2028 | 2029 | ||||
| Estimate breakdown | ||||||||
Financial metrics can be plotted on the graph to see trends. Multiple metrics from multiple statements can be plotted against each other, sourced from Morningstar.
Financials (USD, millions)
| Period end: | DEC 22 | DEC 23 | DEC 24 | DEC 25 |
| Fiscal year: | 2022 | 2023 | 2024 | 2025 |
| Period length: | 12 months | 12 months | 12 months | 12 months |
Displays all company announcements released by the company to the exchange, sourced from Morningstar.
Announcements
Announcements are available for ASX-listed companies only.
Opinion
No opinions for this company yet.
Action
No actions for this company yet.
Business Summary
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
Relevant suggested news and content from the site
Video
WATCH
Webinar Recording: Are commodities entering a Supercycle?
Recorded Wednesday 24th June @ 12.30pm
Podcast
LISTEN
Thursday 11th September – Dow off -220pts, SPI off -20pts
Daily Podcast Direct from the Desk
Video
WATCH
Buy Hold Sell: The 6 income stocks readers love, plus 2 expert ideas
Recorded 10th June 2026
Podcast
LISTEN
Wednesday 10th September – Dow up +196pts, SPI down -4pts
Daily Podcast Direct from the Desk
